LRLarry Luber Martínez Rosado

Larry Luber Martínez Rosado

*This is an algorithmically generated author record based on publicly available information.

Larry Luber Martínez Rosado has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disseminated angiomatous lesions in HIV-seropositive patient

    by Larry Luber Martínez Rosado Luber, Juan David Berlinghieri

    Kaposi’s sarcoma is an uncommon malignant vascular neoplasm linked to human herpesvirus type 8 (HHV-8); it is a tumor characterized by proliferation of HHV-8-associated spindle cells and abnormal neo-vasculature. Although Kaposi’s sarcoma has been described in immunocompetent subjects,...

  • Open Access

    Estenosis laringotraqueal recurrente asociada a Klebsiella pneumoniae subsp. rhinoscleromatis

    by Larry Luber Martínez Rosado, Diana Patricia Pérez Villegas, Adriana Yelitza Isaza Marín, Manuela Hurtado González, Alejandra Mendoza Gallego

    Introduction: Klebsiella rhinoscleromatis (KR) is an enterobacterium associated with the formation of chronic granulomatosis. When this microorganism affects the respiratory tract, it is called scleroma, the nasal cavity is the main one affected; additionally, can involve nasopharynx, larynx, trachea, and bronchi. Clinical case: female patient with a history of chronic laryngotracheitis, with diagnosis of tracheal stenosis and isolation in cultures of multisensitive Klebsiella pneumoniae ssp rhinoscleromatis, without nasosinusal or extralaryngeal involvement. Discussion: scleroma can affect the entire respiratory tract, so associated risk factors should be taken into account, mainly overcrowding, immunosuppression, and female sex, in whom it is more common. The mainstay of treatment is medical, based on antibiotics; additionally, surgical management is reserved for sclerotic stage, when there is no inflammatory phenomenon. Conclusion: scleroma is a rare pathology, with a chronic evolution, with involvement mainly in the nasal cavity, which requires a high diagnostic suspicion for its timely management.

  • Open Access

    Experiencia en el Tratamiento para Hepatitis C en un Hospital de Tercer Nivel de Complejidad en Colombia entre Enero 2017 a Junio De 2020

    by Larry Martínez, Rodrigo Martínez

    La infección por el virus de la hepatitis C (VHC) es una de las principales causas de enfermedad hepática crónica en el mundo 1,2. Con impacto variable, desde cambios mínimos hasta carcinoma hepatocelular (CHC)1. Las infecciones agudas suelen ser asintomáticas y, en su mayor parte; no mortales. Aproximadamente un 30% de las personas infectadas elimina el virus espontáneamente en aproximadamente 6 meses, sin necesidad de tratamiento. El 70% restante (55-85%), la infección se cronifica y así sus riesgos1–3. Según datos de la Organización Mundial de la Salud (OMS) a junio del 2021 se estimaban 58 millones de personas con infección crónica por el VHC; con 1,5 millones de nuevas infecciones anuales2. Se calculó que en 2019 fallecieron cerca de 290 000 personas principalmente por cirrosis y CHC2. Su distribución geográfica varía, siendo mayor hacia el mediterráneo oriental y Europa con aproximadamente 12 millones de casos2. La transmisión es sanguínea; la mayoría por exposición a la sangre por prácticas de inyección o atenciones de salud poco seguras, transfusión de sangre sin analizar, drogas y prácticas sexuales 2–4. Los antivíricos pueden curar más del 95% de los casos, pero el acceso al diagnóstico y el tratamiento es limitado. En la actualidad no existe ninguna vacuna contra el VHC1–3. En nuestro país, se reportaron al Sistema Nacional de Vigilancia en Salud Pública (Sivigila) en el año 2020, 473 casos nuevos de infecciones por hepatitis C, equivalente a una incidencia cruda de 0,9 por 100.000 habitantes5,6. Existen reducidas publicaciones del tópico en la literatura latinoamericana, en Colombia falta investigación sobre grupos clave; como hombres que tienen sexo con otros hombres (HSH), usuarios de drogas inyectables y/o inhaladas, reclusos7. Este estudio analizó fuentes secundarias de forma retrospectiva, de pacientes con diagnóstico de certeza de hepatitis C y que fueron tratados con Antivirales de Acción de Directa (AAD). El análisis fue enfocado en: variables sociales y demográficas, biomarcadores, efectos adversos, consumo de psicoactivos (inhalados) y probable relación con mayor incidencia, genotipo dominante.

  • Open Access

    Co-Infection with Cryptosporidium meleagridis and Enterocytozoon bieneusi in an HIV+ Colombian Patient

    by Carolina Hernández-Castro, Larry L. Martínez-Rosado, Alejandro Dashti, Pamela C. Köster, Begoña Bailo, María C. Orozco, Mónica Santín, David González-Barrio, David Carmena

    A 44-year-old human immunodeficiency virus-infected (HIV+) female with severe immunodeficiency Category 3 (C3) diagnosed in 2010 was admitted to hospital with acute diarrhoea. She was non-adherent to antiretroviral therapy (ART) and had a previous suspicion of respiratory symptoms with a cough that had been persisting for 15 days. Clinical examination revealed severe immune deterioration (viral load: 109,655 copies/mL; CD4+ count: 14 cells/mm3), respiratory symptoms (negative sputum Gram stain and tuberculosis culture), and neurological deterioration (serological assays negative for Cryptococcus spp. and Toxoplasma gondii). A coproculture was negative for Campylobacter spp., Salmonella spp., and Shigella spp. Ziehl–Neelsen staining of faecal smears revealed the presence of Cryptosporidium spp. oocysts. PCR testing and sequencing confirmed a concomitant infection with C. meleagridis and Enterocytozoon bieneusi. The patient was treated with metronidazole (500 mg every 8 h for 5 days) and nitazoxanide (500 mg every 12 h for 14 days). After requesting voluntary discharge and abandoning ART and parasiticidal treatments, she experienced a dramatic deterioration of her state of health and contact with her was lost. Our results have demonstrated that molecular-based testing improves the detection of opportunistic pathogens that are difficult to detect by routine microscopy, allows for transmission dynamics investigations, and assists in choosing the best chemotherapeutical option.


  • Open Access

    In vitro antiviral effect of silver nanoparticles against SARS-CoV-2

    by Lizdany Flórez-Álvarez, Juan C. Hernandez, Wildeman Zapata-Builes, José Iván Charry-Zuluaga, José R. Jaramillo, Natalia A. Taborda, Juan D. Gonzalez, Larry L. Martínez, Lina Maria Yasssin-Noreña

    Introduction: COVID-19 is an acute respiratory tract disease caused by the emerging coronavirus SARS-CoV-2. Although several options for chemoprophylaxis are under development, effective treatment for COVID-19 is not yet available. Objective: To investigate the antiviral properties of synthesized silver nanoparticles (AgNPs) against SARS-CoV-2 using in vitro models. Materials and methods: This work synthesized AgNPs using an electrochemical method and characterized them using physico-chemical techniques (ICP-OES, ultraviolet-visible spectroscopy, and transmission electron microscopy). AgNPs with diameter sizes ranging between 2.6 to 30 nm and an average size of 6.2 nm were obtained by the electrochemical method. The cytotoxic effect and the antiviral activity of prepared AgNPs against SARS-CoV-2 were evaluated in vitro using Vero E6 cells. Cell viability was evaluated by MTT assay in the presence of serial dilutions of AgNPs. The antiviral effect of AgNPs was evaluated before and after the infection of Vero E6 cells by plaque assay. Results: Cytotoxic effect was observed at concentrations above 0.07 ppm. AgNPs exhibit a significant reduction of SARS-CoV-2 viral titer after a pre-post treatment strategy with inhibition of 96.5%, 64.13%, and 74.72% at 0.03, 0.017, and 0.008 ppm, respectively. Conclusion: Our results suggest that AgNPs could reduce SARS-CoV-2 replication with a low cytotoxic effect. Still, additional in vitro and in vivo studies are required to define its potential therapeutic application in humans.